Health Topic

Hepatology

A commitment to effective HCV and HBV diagnosis and monitoring since 1993

Hepatitis B and C are among the most common viral infections in the world. About 325 million worldwide in 2015 were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2

Every day, approximately 4,000 people die from the consequences of viral hepatitis – 1.4 million people every year.3 Furthermore, each year, 1.75 million people newly acquire hepatitis C virus infection. The disease caused 1.34 million deaths in 2015, a number comparable to annual deaths caused by tuberculosis and higher than those caused by HIV.2

Roche is committed to fighting viral hepatitis, offering a complete continuum of care for the diagnosis and treatment of HCV and HBV. This starts with a focus on  serology based testing for screening and diagnosis followed by PCR testing for confirmation and genotyping (only HCV) and viral load monitoring to determine patient response to treatment.

90% reduction in new cases of chronic hepatitis B and C by 2030

References

 

  1. World Hepatitis Alliance What is Viral Hepatitis. Updated 2018 Last accessed November 29, 2018 at http://www.worldhepatitisalliance.org/what-viral-hepatitis-0
  2. World Health Organization. Global Hepatitis Report 2017. http://www.who.int/who-campaigns/world-hepatitis-day/2018 Accessed November 28, 2018
  3. World Health Organization. World Hepatitis Day. Last accessed July 2016 at http://www.who.int/campaigns/hepatitis-day/2016/event/en/
  4. WHO Combating hepatitis B and C to reach elimination by 2030 Publication date July 2016 Last accessed November 29 2018 at https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/
Products
Category
Found 0 results in
Filters
...
    ...